



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

To,

Date: 30.05.2017

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2017

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s. Concord Drugs Limited held on Tuesday, 30.05.2017 at 10:00 a.m. at the registered office of the company at Survey No.249, Brahmanapally Village, Hayatnagar Mandal -501511, Telangana, the following were considered and approved:

1. Audited financial results for the quarter ended 31.13.2017. (Attached)
2. Declaration u/r 33 of SEBI (LODR) Regulations, 2015. (Attached)

The meeting concluded at 7.00 p.m

This is for the information and records of the Exchange, please.

Thanking you.


Yours faithfully,
For Concord Drugs Limited

S. Nagi Reddy
S. Nagi Reddy
Chairman
DIN: 01764665



Encl: as above





CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

SCHEDULE III OF COMPANIES ACT, 2013

PART I - AUDITED BALANCE SHEET FOR THE FY 2016-17

Name of the Company - **M/s. CONCORD DRUGS LIMITED**

Balance Sheet as at **31st March, 2017**

(Rupees in Lacs)


Particulars	STANDALONE	
	As at 31/03/2017	As at 31/03/2016
I EQUITY AND LIABILITIES		
1. Share Holders' Funds:		
(a) Share Capital	724.38	724.38
(b) Reserves and Surplus	798.13	782.18
(c) Money received against Share Warrants	-	-
Sub-Total - Share Holders' Funds	1,522.51	1,506.56
2 Non Current Liabilities:		
(a) Long Term Borrowings	1,062.82	1,220.56
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	9.29	426.37
3 Current Liabilities		
(a) Short Term Borrowings	926.08	778.29
(b) Trade Payables	-	-
A total outstanding dues of micro enterprises and small enterprises	-	-
total outstanding dues of creditors other than micro enterprises and		
B small enterprises	3,586.47	981.74
(c) Other Current Liabilities	328.70	127.77
(d) Short Term Provisions	39.37	189.92
TOTAL	7,475.24	5,231.21
II ASSETS		
1. Non-Current Assets:		
(a) Fixed Assets		
(i) Tangible Assets	1,363.52	1,517.55
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible assets under development	-	-
(b) Non-Current Investments	-	-
(c) Deferred Tax Assets (Net)	(27.36)	(17.94)
(d) Long Term Loans and Advances	114.55	79.04
(e) Other Non-Current Assets	-	-
2. Current Assets:		
(a) Current Investments	-	-
(b) Inventories	1,102.70	814.85
(c) Trade Receivables	4,573.15	2,547.91
(d) Cash & Cash Equivalents	17.14	3.57
(e) Short Term Loans and Advances	90.71	149.74
(f) Other Current Liabilities	240.83	136.49
TOTAL	7,475.24	5,231.21

For M/s. CONCORD DRUGS LIMITED

Place : Hyderabad
Date : 30/05/2017

S. N. R. Reddy
Managing Director





CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

SCHEDULE III OF COMPANIES ACT, 2013					
PART II - AUDITED STATEMENT OF PROFIT AND LOSS FOR THE FY 2016-17					
Name of the Company - M/s. CONCORD DRUGS LIMITED					
Profit and Loss Statement for the year ended 31st March, 2017					
(Rs. In Lakhs)					
Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
	Audited	Unaudited	Audited	Audited	Audited
I Revenue From Operations	2,143.08	921.45	1,396.28	5748.97	5,068.29
II Other Income	2.72	2.31	2.84	8.57	20.31
III Total Revenue (I+II)	2,145.80	923.76	1,399.12	5,757.54	5,088.60
IV Expenses					
Cost of Materials Consumed	1,708.19	733.44	1,083.51	4,650.89	3,921.88
Purchases of Stock-in-trade		-	-	-	-
Changes in inventories of finished goods	308.00	(279.74)	16.66	(40.38)	(27.51)
Work-in-progress and Stock-in-trade	-	-	-	-	-
Employee benefits expense	104.41	64.91	85.05	280.65	161.37
Finance Costs	71.28	52.71	57.18	235.99	257.32
Depreciation and Amortisation expense	71.73	64.21	63.11	258.40	291.18
Other Expenses	96.47	96.65	54.59	307.24	188.01
Total Expenses	2,360.08	732.18	1,360.10	5,692.79	4,792.25
V Profit/ (Loss) before Exceptional and Extraordinary Items and tax (III-IV)	(214.28)	191.58	39.02	64.75	296.35
VI Exceptional Items	-	-	-	-	-
VII Profit/ (Loss) before Extraordinary Items and tax (V-VI)	(214.28)	191.58	39.02	64.75	296.35
VIII Extraordinary Items	-	-	-	-	-
IX Profit/ (Loss) before Tax (VI-VIII)	(214.28)	191.58	39.02	64.75	296.35
X Tax Expense:					
Current Tax	(46.06)	59.20	(13.52)	39.37	117.40
Deferred Tax	9.42	-	-	9.42	4.09
XI Profit/ (Loss) for the period from continuing operations (VII-XIII)	(177.64)	132.38	52.54	15.96	174.86
XII Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XIII Tax Expense of discontinuing operations	-	-	-	-	-
XIV Profit/ (Loss) from discontinuing operations after tax (XII-XIII)	-	-	-	-	-
XV Profit/ (Loss) for the period (XI+XIV)	(177.64)	132.38	52.54	15.96	174.86
XVI Earnings Per Share (EPS)					
Basic	(2.45)	1.83	0.73	0.22	2.41
Diluted	(2.45)	1.83	0.73	0.22	2.41

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Tuesday, 30th May, 2017.
- The Audited Financial Results for the Quarter IV and Year ended 31st March, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- Export order of product "ISO AMCRYLATE" has failed due to the quality specifications are not met, hence the stock these product has been considered as consumption in raw material and to that extent the company has incurred losses for the Quarter ended 31st March, 2017.
- The results are also available on the webiste of the Company www.concorddrugs.in
- The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto third quarter of the respective financial year

For M/s. CONCORD DRUGS LIMITED

Place : Hyderabad
Date : 30/05/2017

S. N. R.
Managing Director





M M REDDY & CO.,
Chartered Accountants

Phone : 040-23418836
040-40272617
Mobile : 98482 71555

**Auditor's Report on Quarterly Financial Results and Year to Date Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015**

To
Board of Directors of
M/s. Concord Drugs Limited.

We have audited the quarterly financial results of M/s. Concord Drugs Limited ("The Company") for the quarter ended 31st March, 2017 and the year to date financial results for period from 01st April 2016 to 31st March, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.




In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- I. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- II. give a true and fair view of the financial performance and other financial information for the quarter ended 31st March, 2017 as well as the year to date financial results for period from 01st April 2016 to 31st March, 2017.

The financial results includes the results for the Quarter ended 31st March, 2017 being the balancing figure audited between the audited figures in respect of the full financial year and audited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M M REDDY & CO.
Chartered Accountants
Firm Registration No.010371S


M. Madhusudhana Reddy
Partner
Membership No.213077



Place: Hyderabad
Date: 30.05.2017



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 30.05.2017

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I. S. Nagi Reddy, Chairman of Concord Drugs Limited hereby declare that, the statutory Auditors of the company, M/s. M M Reddy & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2017.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Nagi Reddy
S. Nagi Reddy
Chairman
DIN: 01764665

